Gene therapy for vestibular schwannoma, a non-cancerous tumor on the hearing nerve
Tests the safety of AAVAnc80-antiVEGF gene therapy in adults with vestibular schwannoma.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Baltimore, Dallas, Nashville, and Rochester, United StatesSee the 4 sites
- Trial code
- Registry title
- Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 27 people, planned
- Started
- 17 Jan 2025
- Expected to end
- Aug 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a vestibular schwannoma (a non-cancerous tumour on the hearing and balance nerve) on one side that is growing. They must have profound hearing loss in that ear.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Vestibular schwannoma on one side only, growing, larger than 2 mm. Profound hearing loss in the affected ear, measured by hearing tests.
- Earlier treatment
- People cannot have had surgery or radiation therapy for the vestibular schwannoma before. People cannot have taken part in any gene therapy trial before.
Main reasons for not taking part
- A diagnosis of NF2, or vestibular schwannoma in both ears
- Past surgery or radiation therapy for the vestibular schwannoma
- History of fluid build-up in the inner ear (changing hearing loss or repeated spells of dizziness) in the affected ear
- Profound hearing loss in the other ear
- Took part in a trial of an experimental drug within six months before the treatment day, or ever took part in a gene therapy trial
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Criteria for Inclusion:
- Presence of unilateral, progressive vestibular schwannoma
- Vestibular schwannoma larger than 2 mm
- Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the affected ear
- Able and willing to comply with all trial requirements, including willingness to participate in a separate long term follow-up study after completion of this trial; Criteria for Exclusion:
- Prior diagnosis of NF2 and/or bilateral vestibular schwannoma
- Prior surgery or radiation therapy for vestibular schwannoma
- Clinical history consistent with endolymphatic hydrops (documented fluctuating sensorineural hearing loss and/or episodic vertigo) in the affected ear
- Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the unaffected ear
- Prior participation in a clinical trial with an investigational drug within six months prior to administration (Day 0), or any prior participation in a gene therapy clinical trial
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesContact: Lilly Clinical TrialsTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Lilly Clinical TrialsTaking people
- Vanderbilt Bill Wilkerson CenterNashville, United StatesContact: Taha Jan, MDTaking people
- Mayo ClinicRochester, United StatesContact: Dan OslandTaking people
About the trial
What the trial wants to find out
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
The 3 groups in the trial
- Cohort 1Treatment being tested
Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 1) in the study ear using a sterile, one-time use investigational medical device.
Treatment: AAVAnc80-antiVEGF via Akouos Delivery Device
- Cohort 2Treatment being tested
Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 2) in the study ear using a sterile, one-time use investigational medical device.
Treatment: AAVAnc80-antiVEGF via Akouos Delivery Device
- Cohort 3Treatment being tested
Adult participants to receive a single unilateral intracochlear administration of AAVAnc80-antiVEGF (dose level 3) in the study ear using a sterile, one-time use investigational medical device
Treatment: AAVAnc80-antiVEGF via Akouos Delivery Device
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
- Plain-language title
- Gene therapy for vestibular schwannoma, a non-cancerous tumor on the hearing nerveGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 4 November 2026